These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34176937)

  • 1. Baseline Neutrophil-to-Lymphocyte Ratio and Glasgow Prognostic Score are Associated with Clinical Outcome in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
    Chikuie N; Hamamoto T; Ueda T; Taruya T; Kono T; Furuie H; Ishino T; Takeno S
    Acta Med Okayama; 2021 Jun; 75(3):335-343. PubMed ID: 34176937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Taura M; Uchi R; Nakagawa T
    Oral Oncol; 2020 Feb; 101():104525. PubMed ID: 31863963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score.
    Ueki Y; Takahashi T; Ota H; Shodo R; Yamazaki K; Horii A
    Eur Arch Otorhinolaryngol; 2020 Aug; 277(8):2341-2347. PubMed ID: 32239313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy.
    Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Jiromaru R; Manako T; Nakagawa T
    In Vivo; 2022; 36(2):907-917. PubMed ID: 35241549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation and comparison of prognostic scoring systems in patients with head and neck squamous cell carcinoma treated with nivolumab.
    Takenaka Y; Takemoto N; Otsuka T; Nishio M; Tanida M; Fujii T; Hayashi K; Suzuki M; Mori M; Yamamoto Y; Uno A; Inohara H
    Jpn J Clin Oncol; 2024 Jul; 54(7):761-769. PubMed ID: 38555496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients.
    Matsuki T; Okamoto I; Fushimi C; Sawabe M; Kawakita D; Sato H; Tsukahara K; Kondo T; Okada T; Tada Y; Miura K; Omura G; Yamashita T
    Cancer Med; 2020 Jul; 9(14):5015-5024. PubMed ID: 32441463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.
    Bilen MA; Dutcher GMA; Liu Y; Ravindranathan D; Kissick HT; Carthon BC; Kucuk O; Harris WB; Master VA
    Clin Genitourin Cancer; 2018 Jun; 16(3):e563-e575. PubMed ID: 29402706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma.
    Fushimi C; Okamoto I; Matsuki T; Masubuchi T; Okada T; Sato H; Tsukahara K; Kondo T; Yamashita T; Hanyu K; Omura GO; Takahashi H; Tada Y; Miura K
    Anticancer Res; 2020 Sep; 40(9):5277-5283. PubMed ID: 32878817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab.
    Tanoue K; Tamura S; Kusaba H; Shinohara Y; Ito M; Tsuchihashi K; Shirakawa T; Otsuka T; Ohmura H; Isobe T; Ariyama H; Koreishi S; Matsushita Y; Shimokawa H; Tanaka R; Mitsugi K; Akashi K; Baba E
    Sci Rep; 2021 Feb; 11(1):2741. PubMed ID: 33531609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer.
    Suzuki C; Kiyota N; Imamura Y; Rikitake J; Sai S; Koyama T; Hyogo Y; Nagatani Y; Funakoshi Y; Toyoda M; Otsuki N; Nibu KI; Minami H
    Int J Clin Oncol; 2020 Jul; 25(7):1270-1277. PubMed ID: 32277393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab.
    Nishikawa D; Suzuki H; Beppu S; Terada H; Sawabe M; Kadowaki S; Sone M; Hanai N
    Cancer Sci; 2021 Jan; 112(1):339-346. PubMed ID: 33078505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
    Saba NF; Wong SJ; Nasti T; McCook-Veal AA; McDonald MW; Stokes WA; Anderson AM; Ekpenyong A; Rupji M; Abousaud M; Rudra S; Bates JE; Remick JS; Joshi NP; Woody NM; Awan M; Geiger JL; Shreenivas A; Samsa J; Ward MC; Schmitt NC; Patel MR; Higgins KA; Teng Y; Steuer CE; Shin DM; Liu Y; Ahmed R; Koyfman SA
    JAMA Oncol; 2024 Jul; 10(7):896-904. PubMed ID: 38780927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma.
    Okada T; Fushimi C; Matsuki T; Okamoto I; Sato H; Kondo T; Tokashiki K; Kishida T; Ito T; Yamashita G; Aihara Y; Hanyu K; Kushihashi Y; Masubuchi T; Tada Y; Miura K; Harada Y; Momiyama K; Yamashita T; Omura GO; Takahashi H; Oridate N; Tsukahara K
    Anticancer Res; 2022 Mar; 42(3):1607-1613. PubMed ID: 35220258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy.
    Chandrasekara S; Davis S; Thomson P; Haydon A
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e442-e447. PubMed ID: 29345108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab.
    Ueda T; Chikuie N; Takumida M; Furuie H; Kono T; Taruya T; Hamamoto T; Hattori M; Ishino T; Takeno S
    Acta Otolaryngol; 2020 Feb; 140(2):181-187. PubMed ID: 31825711
    [No Abstract]   [Full Text] [Related]  

  • 16. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
    Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
    Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
    Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
    Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
    Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
    Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.
    Bojaxhiu B; Templeton AJ; Elicin O; Shelan M; Zaugg K; Walser M; Giger R; Aebersold DM; Dal Pra A
    Radiat Oncol; 2018 Nov; 13(1):216. PubMed ID: 30400969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Economopoulou P; Kotsantis I; Papaxoinis G; Gavrielatou N; Anastasiou M; Pantazopoulos A; Kavourakis G; Gkolfinopoulos S; Panayiotides I; Delides A; Psyrri A
    Oral Oncol; 2020 Dec; 111():105013. PubMed ID: 32977184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.